Longer Look Confirms Nesiritide's Flop

HFSA 2011 — BOSTON — Six-month follow-up in the ASCEND-HF trial confirmed a lack of significant clinical benefit -- or harm -- from nesiritide (Natrecor) in patients with acute decompensated heart failure, researchers found.


< Back to Listings